Literature DB >> 21118414

Determinants of masked hypertension in hypertensive patients treated in a primary care setting.

A Andalib1, S Akhtari, R Rigal, G Curnew, J-M Leclerc, M Vaillancourt, J-C Tardif.   

Abstract

BACKGROUND: Recent data suggest that masked hypertension (MH) carries a cardiovascular risk similar to that of uncontrolled hypertension. AIMS: The objective of this study was to determine the prevalence and determinants of MH in patients treated for hypertension in a Canadian primary care setting.
METHODS: Office blood pressure (OBP) was measured at baseline and after 3 months of valsartan-based therapy in 5636 hypertensive patients who had recorded their home blood pressure monitoring (HBPM) for seven consecutive days at month 3 using an Omron HEM-711 apparatus. MH was defined in nondiabetic patients as an OBP <140/90 mmHg and an HBPM ≥135/85 mmHg, and in those with diabetes as an OBP <130/80 mmHg and an HBPM ≥125/75 mmHg.
RESULTS: Of the 5636 patients, 1025 had diabetes. OBP was controlled at 3 months in 268 (26.1%) of them, but 167 (62.3%) had MH. OBP was controlled in 2728 (59.1%) of the 4611 patients without diabetes, and 935 (34.3%) of them had MH. Overall, 1102 patients had MH, representing 36.8% of patients with controlled OBP and 19.6% of the entire hypertensive study population. Stepwise multiple logistic regression analysis in nondiabetic patients with controlled OBP at 3 months revealed that older age, male sex, higher body mass index and higher office systolic blood pressure were determinants of MH.
CONCLUSION: Our results indicate that one of five hypertensive patients and more than one of three with controlled OBP will have MH. MH is associated with other cardiovascular risk factors, such as diabetes, and in nondiabetics, with male sex, older age and obesity.
© 2010 The Authors. Internal Medicine Journal © 2010 Royal Australasian College of Physicians.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21118414     DOI: 10.1111/j.1445-5994.2010.02407.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  11 in total

Review 1.  The 2015 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: An update.

Authors:  Sherilyn K D Houle; Raj Padwal; Luc Poirier; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2015-07

2.  Hypertension Canada's 2016 Canadian Hypertension Education Program guidelines for pharmacists: An update.

Authors:  Yazid N Al Hamarneh; Sherilyn K D Houle; Raj Padwal; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2016-10-06

3.  Masked hypertension.

Authors:  Wilbert S Aronow
Journal:  Ann Transl Med       Date:  2017-12

4.  Could self-measured office blood pressure be a hypertension screening tool for limited-resources settings?

Authors:  Martin R Salazar; Walter G Espeche; Rodolfo N Stavile; Eduardo Balbín; Betty C Leiva Sisnieguez; Carlos E Leiva Sisnieguez; Carlos E March; Susana Cor; Irma Eugenio Acero; Horacio A Carbajal
Journal:  J Hum Hypertens       Date:  2018-05-01       Impact factor: 3.012

5.  Diagnosis of true uncontrolled hypertension using both home and ambulatory blood pressure monitoring.

Authors:  K Kario
Journal:  J Hum Hypertens       Date:  2013-08-08       Impact factor: 3.012

6.  Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients with diabetes: results of the POWER survey.

Authors:  Robert J Petrella; Dawn P Gill; Jean-Pascal Berrou
Journal:  Diabetes Metab Syndr Obes       Date:  2015-03-24       Impact factor: 3.168

7.  The impact of different anthropometric measures on sustained normotension, white coat hypertension, masked hypertension, and sustained hypertension in patients with type 2 diabetes.

Authors:  Baris Afsar
Journal:  Endocrinol Metab (Seoul)       Date:  2013-09-13

8.  Blood Pressure Control in Hypertensive Patients, Cardiovascular Risk Profile and the Prevalence of Masked Uncontrolled Hypertension (MUCH).

Authors:  Nabil Naser; Alen Dzubur; Azra Durak; Mehmed Kulic; Nura Naser
Journal:  Med Arch       Date:  2016-07-27

9.  Masked hypertension in diabetes mellitus: treatment implications for clinical practice.

Authors:  Stanley S Franklin; Lutgarde Thijs; Yan Li; Tine W Hansen; José Boggia; Yanping Liu; Kei Asayama; Kristina Björklund-Bodegård; Takayoshi Ohkubo; Jørgen Jeppesen; Christian Torp-Pedersen; Eamon Dolan; Tatiana Kuznetsova; Katarzyna Stolarz-Skrzypek; Valérie Tikhonoff; Sofia Malyutina; Edoardo Casiglia; Yuri Nikitin; Lars Lind; Edgardo Sandoya; Kalina Kawecka-Jaszcz; Jan Filipovsky; Yutaka Imai; Jiguang Wang; Hans Ibsen; Eoin O'Brien; Jan A Staessen
Journal:  Hypertension       Date:  2013-03-11       Impact factor: 10.190

10.  Predicting Out-of-Office Blood Pressure in the Clinic (PROOF-BP): Derivation and Validation of a Tool to Improve the Accuracy of Blood Pressure Measurement in Clinical Practice.

Authors:  James P Sheppard; Richard Stevens; Paramjit Gill; Una Martin; Marshall Godwin; Janet Hanley; Carl Heneghan; F D Richard Hobbs; Jonathan Mant; Brian McKinstry; Martin Myers; David Nunan; Alison Ward; Bryan Williams; Richard J McManus
Journal:  Hypertension       Date:  2016-03-21       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.